CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,310,688 | -19.3% | 94,970 | -0.2% | 0.25% | -17.1% |
| Q2 2023 | $5,341,833 | +27.6% | 95,152 | +2.8% | 0.30% | +19.1% |
| Q1 2023 | $4,185,313 | +31.5% | 92,534 | +18.2% | 0.25% | +14.6% |
| Q4 2022 | $3,182,895 | -36.0% | 78,300 | +2.9% | 0.22% | -36.9% |
| Q3 2022 | $4,972,000 | +69.9% | 76,085 | +58.0% | 0.35% | +57.7% |
| Q2 2022 | $2,926,000 | +7.8% | 48,149 | +11.4% | 0.22% | +41.9% |
| Q1 2022 | $2,714,000 | -17.2% | 43,237 | 0.0% | 0.16% | -6.6% |
| Q4 2021 | $3,276,000 | -27.6% | 43,237 | +7.0% | 0.17% | -32.5% |
| Q3 2021 | $4,522,000 | -30.1% | 40,399 | +1.1% | 0.25% | -30.9% |
| Q2 2021 | $6,467,000 | +19.5% | 39,947 | -10.0% | 0.36% | +8.9% |
| Q1 2021 | $5,410,000 | -49.0% | 44,398 | -36.0% | 0.33% | -47.3% |
| Q4 2020 | $10,618,000 | +85.5% | 69,349 | +1.3% | 0.62% | +59.8% |
| Q3 2020 | $5,724,000 | – | 68,433 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |